Press release
New technology acquisition provides Unither Pharmaceuticals with specialized transmucosal paracetamol solutions
Preliminary clinical trials have shown that this technology would enable to lower the dosage of paracetamol while keeping the same effect as traditional dosage for oral forms.The deal comes after previous patents acquisitions by Unither Pharmaceuticals in the last years related to oro-dispersible formulations.
This addition will further enhance Unither Pharmaceuticals capabilities to deliver innovative solutions through its recently launched ODTechTM platform, offering several solid and liquid stick packs technologies.
Unither Pharmaceuticals’ CEO, Eric Goupil, said:
"This deal represents an important milestone for Unither Pharmaceuticals and its commitment to invest in R&D to facilitate patients’ daily life by developing affordable, convenient and easy to use products”
“It is also a significant addition to our ODTech platform, putting us in a very unique position with a multi-technology oral single dose strategy".
Unither Pharmaceuticals’ Head of Innovation & Development, Nathalie Masson, commented:
"Our clients are looking for medicines with a shorter onset of action, especially when dealing with painkillers, to deliver great experiences to their customers.
This new technology will allow us to present a truly differentiated offering, enabling us to deliver innovative solutions to patients who want a faster acting painkiller. It will also support one of the firm's strategic priorities to further embed convenience into its products."
Unither Pharmaceuticals is the global leader in sterile unit-dose contract manufacturing. We provide expertise utilizing innovative and niche technologies such as: sterile unit-dose Blow- Fill- Seal Technology (BFS), liquid stick pack, powder stick pack, oral liquids and suspensions, orodispersible solutions and extended release formulations. We produce 2.4 billion BFS doses and 260 million liquid packs annually, sold in more than 100 countries.
3-5 rue saint-georges, Paris 75009 France
unither@unither-pharma.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release New technology acquisition provides Unither Pharmaceuticals with specialized transmucosal paracetamol solutions here
News-ID: 1709799 • Views: …
More Releases from Unither Pharmaceuticals
Unither Pharmaceuticals has completed the purchase of the Novartis site located …
Paris (France), 12/07/2022 - Unither Pharmaceuticals, the world's leading manufacturer of sterile unit-dose products, recently acquired the Novartis plant in São Paulo, Brazil, as a new step in its industrial expansion in Brazil.
« This acquisition enables us to benefit from sterile operations in Latin America and to enlarge our offer to multidose ophthalmic containers. We are pleased to welcome the 180 people joining Unither Pharmaceuticals and bring new possibilities to…
Unither Pharmaceuticals initiated the acquisition of Nanjing Ruinian Best Pharma …
Paris (France) and Nanjing (China), August 25th, 2020 – Unither Pharmaceuticals, a global leader in sterile single dose technology, initiated today the acquisition of Nanjing Ruinian Best Pharmaceutical Co. Ltd, a Chinese pharmaceutical company.
With this acquisition, Unither is accelerating the development of its business in China, the second largest market in the world, and complementing the worldwide Unither industrial footprint in Europe, the US and Brazil. “We are delighted…
More Releases for Pharmaceuticals’
Cystic fibrosis Market: Epidemiology, Therapies, Companies, DelveInsight | Veron …
Cystic fibrosis therapies, such as TRIKAFTA, SYMDEKO, KALYDECO, VX-121/TEZ/ VX-561, Ensifentrine, and others, are expected to boost the Cystic fibrosis Market in the upcoming years.
DelveInsight has launched a new report on "Cystic fibrosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Cystic fibrosis, historical and forecasted epidemiology as well as the Cystic fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Gastritis Drugs Market Size Report 2032 | Regeneron Pharmaceuticals, Sanofi, Han …
DelveInsight's "Gastritis Market Insights, Epidemiology, and Market Forecast -2032" report delivers an in-depth understanding of the Gastritis, historical and forecasted epidemiology as well as the Gastritis market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.
Key Takeaways from the Gastritis Market Research Report
• The increase in Gastritis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging…
Generic Pharmaceuticals Market Set for More Growth| Hikma Pharmaceuticals, Emcur …
Advance Market Analytics published a new research publication on "Generic Pharmaceuticals Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Generic Pharmaceuticals market was mainly driven by the increasing R&D spending across the world.
Get Free Exclusive PDF Sample Copy of…
Global Halal Pharmaceuticals Market 2019 - CCM Pharmaceuticals, Pharmaniaga, Ros …
This new report by Eon Market Research, titled “Global Halal Pharmaceuticals Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Halal Pharmaceuticals industry at a global as well as regional and country level. Key facts analyzed in this report include the Halal Pharmaceuticals market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study…
Topical Antibiotic Pharmaceuticals Market 2016-2026 | Teva Pharmaceuticals, Perr …
Topical antibiotics are applied to a certain area of the skin to kill infections. Application of topical antibiotics has a number of advantages upon comparison of systemic delivery in the treatment of skin infections. Skin and soft tissue infections (SSTIs) involve microbial invasion of the skin and underlying soft tissues infections are one of the most commonly occurring conditions amongst people. Most of these infections are minor and chronic in…
Lipid Disorder Treatment Market to 2017 - 2026: Teva Pharmaceuticals, Mylan Phar …
Researchmoz added Most up-to-date research on "Lipid Disorder Treatment Market - Global Industry Analysis, Share, Size, Growth, Trends and Forecast 2017 - 2026" to its huge collection of research reports
Extensive research report on global lipid disorders treatment market skilfully crafted by Transparency Market Research depicts the current as well as future scenario of various drugs used to treat lipid disorders. The research study includes analysis on key developments that are…
